本文選題：欣普貝生 + 胎膜早破��； 參考：《現(xiàn)代婦產(chǎn)科進(jìn)展》2017年03期

【摘要】：目的:探討欣普貝生(地諾前列酮栓)在足月胎膜早破初產(chǎn)孕婦中應(yīng)用的安全性及有效性。方法:100例足月胎膜早破單胎孕婦,破膜2h后未臨產(chǎn),宮頸條件未成熟(宮頸Bishop評(píng)分≤4分),孕婦知情同意后欣普貝生組入組50例,催產(chǎn)素組50例。比較兩組的分娩方式及母兒結(jié)局情況。結(jié)果:與催產(chǎn)素組比較,欣普貝生組8h、12h促宮頸成熟總有效率明顯增加(92.0%vs 64.5%,P0.01;95.9%vs 79.2%,P0.05)。欣普貝生組陰道分娩率明顯升高(86.0%vs 60.0%,P0.01),且欣普貝生組用藥12h、24h內(nèi)陰道分娩率亦顯著提高(42.0%vs 8.0%,P0.001;64.0%vs 34.0%,P0.01)。欣普貝生組用藥至臨產(chǎn)、用藥至陰道分娩時(shí)間明顯短于催產(chǎn)素組[(7.4±1.0)h vs(14.2±2.0)h,P0.01;(15.4±1.4)h vs(21.4±1.6)h,P0.01]。欣普貝生組引產(chǎn)失敗率、絨毛膜羊膜炎發(fā)生率顯著降低(2.0%vs 16.0%,P0.05;0 vs 12.0%,P0.05);兩組急產(chǎn)、胎兒宮內(nèi)窘迫、相對性頭盆不稱發(fā)生率無明顯統(tǒng)計(jì)學(xué)差異;兩組均無產(chǎn)后出血、新生兒窒息。結(jié)論:足月胎膜早破且宮頸條件未成熟的初產(chǎn)孕婦,應(yīng)用欣普貝生促宮頸成熟安全、有效,且效果優(yōu)于直接催產(chǎn)素引產(chǎn),但用藥期間應(yīng)加強(qiáng)母兒監(jiān)護(hù)。
[Abstract]:Objective: to investigate the safety and efficacy of simplex prostaglandone suppository in pregnant women with term premature rupture of membranes. Methods one hundred pregnant women with single term premature rupture of membranes were enrolled in the study. After 2 hours of rupture, the delivery was not imminent and the cervix condition was immature (cervical Bishop score 鈮，

本文編號(hào)：1814036